NCT05623852

The Impact of Oligo-Fucoidan in Cancer Cachexia and Sarcopenia

A Phase II Trial for Oligo-Fucoidan in Cancer Cachexia and Sarcopenia

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 100 (estimated)
• Sponsor: Taipei Medical University WanFang Hospital · Academic / Other
• Sex: All
• Age: 20 Years – 90 Years
• Healthy volunteers: Not accepted

Summary

Fucoidan also ameliorates tumour and chemotherapy-induced muscle atrophy and -related cachectic symptoms in vivo and in vitro. To evaluate the effect of fucoidan in cancer cachexia or sarcopenia in cancer patients.

Detailed description

Cancer cachexia is characterized by anorexia, skeletal muscle atrophy, and systemic inflammation. Fucoidan extracted from brown algae exhibits anti-inflammatory and anticancer activities. In addition, fucoidan also ameliorates tumour and chemotherapy-induced muscle atrophy and -related cachectic symptoms in vivo and in vitro. To evaluate the effect of fucoidan in cancer cachexia or sarcopenia in cancer patients.

Conditions

• Cachexia

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	fucoidan	It is recommended to consume on an empty stomach, 2 servings per day, a total of 8 tablets, which can be eaten at one time or in divided doses. If it is difficult to swallow, the powder in the capsule can also be taken out and mixed with food or liquid food.

Timeline

• Start date: 2022-01-30
• Primary completion: 2024-04-30
• Completion: 2025-04-30
• First posted: 2022-11-21
• Last updated: 2022-11-21

Locations

2 sites across 1 country: Taiwan